Barclays Maintains Equal-Weight on Biogen, Lowers Price Target to $294
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Equal-Weight rating on Biogen (NASDAQ:BIIB) and lowers the price target from $311 to $294.
August 08, 2023 | 10:39 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays has maintained an Equal-Weight rating on Biogen and lowered the price target from $311 to $294.
The lowering of the price target by Barclays indicates a less optimistic outlook for Biogen, which could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100